Infinity Pharmaceuticals Inc의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
Infinity Pharmaceuticals Inc은 수익성이 있나요?
Infinity Pharmaceuticals Inc에 부채가 있나요?
Infinity Pharmaceuticals Inc의 발행 주식은 몇 주인가요?
주요 통계
이전 종가
$0.0001
시가
$0
일일 범위
$0 - $0.0001
52주 범위
$0 - $0.0001
거래량
109.4K
평균 거래량
47
EPS(TTM)
-0.46
배당수익률
--
시가총액
$9.0K
INFIQ란 무엇인가요?
Infinity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the business of developing novel medicines for people with cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 30 full-time employees. The company went IPO on 2000-07-27. The firm is focused on advancing eganelisib, also known as IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that reprograms macrophages through selective inhibition of the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma). Its eganelisib clinical development program includes MAcrophage Reprogramming in Immuno-Oncology-3 (MARIO-3), MARIO-275 and MARIO-1. MARIO-3 is a multi-arm Phase II study designed to evaluate eganelisib in the front-line treatment for both metastatic triple-negative breast cancer (TNBC), and renal cell carcinoma (RCC). MARIO-275 is its global, randomized, placebo-controlled Phase II study evaluating the effect of adding eganelisib to nivolumab, also known as Opdivo, in checkpoint-naive advanced urothelial cancer (UC). MARIO-1 is in the Phase I/Ib clinical study.